All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LSALT peptide
Therapeutic Area: Infections and Infectious Diseases Product Name: Metablok
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $0.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 29, 2020
Details:
The proceeds supplement the Government of Canada’s commitment of up to $6.7 million for the Phase II development of Metablok (LSALT Peptide), the Company’s therapeutic drug candidate to prevent organ inflammation and injury in patients hospitalized with COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LSALT peptide
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Metablok
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
The Phase II trial is an international, multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide (Metablok) as prevention of organ inflammation known to trigger ARDS and acute kidney injury (AKI) in patients infected with COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LSALT peptide
Therapeutic Area: Infections and Infectious Diseases Product Name: Metablok
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2020
Details:
The Phase II trial is an international, multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of organ inflammation known to trigger acute respiratory distress syndrome (and acute kidney injury in COVID-19 patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LSALT peptide
Therapeutic Area: Infections and Infectious Diseases Product Name: Metablok
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
Arch is planning to expand the existing Phase II trial of LSALT peptide about to begin in the U.S. by adding hospital sites in İstanbul and Ankara, Turkey.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LSALT peptide
Therapeutic Area: Infections and Infectious Diseases Product Name: Metablok
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
Details:
Arch Biopartners received independent Institutional Review Board (IRB) approval for the Phase II trial of its lead drug LSALT peptide (Metablok) targeting acute lung injury and acute kidney injury caused by inflammation in patients with severe cases of COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LSALT peptide
Therapeutic Area: Infections and Infectious Diseases Product Name: Metablok
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
The Phase II trial will be a randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of organ inflammation known to trigger acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LSALT peptide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2020
Details:
The submission of the IND application was made by Arch following several weeks of review of the Company’s Phase II study for LSALT peptide in COVID-19 by the FDA under the Coronavirus Treatment Acceleration Program.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LSALT peptide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2020
Details:
The expansion of primary endpoint of the Phase II human trial for LSALT reflects recent global data from COVID-19 patients that shows the SARS-CoV-2 virus results in damage to organs besides the lungs and Metablok’s potential to prevent inflammation injury in multiple organs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LSALT peptide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2020
Details:
The Phase II trial will be a multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LSALT peptide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020
Details:
The Phase II trial will be a multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
